Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 6, Issue 9, pp. 1093-1099
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 26, 2017
- Revision received April 21, 2018
- Accepted July 5, 2018
- Published first July 10, 2018.
Article Versions
- Previous version (July 10, 2018 - 06:44).
- Previous version (August 9, 2018 - 06:46).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Fernando C. Santini1,2,
- Hira Rizvi3,
- Andrew J. Plodkowski4,
- Andy Ni5,
- Mario E. Lacouture6,
- Maya Gambarin-Gelwan7,
- Olivia Wilkins1,
- Elizabeth Panora8,
- Darragh F. Halpenny4,
- Niamh M. Long4,
- Mark G. Kris1,9,
- Charles M. Rudin1,3,9,
- Jamie E. Chaft1,9, and
- Matthew D. Hellmann1,9,10,*
- 1Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 2Oncology Center, Hospital Sirio-Libanês, Sao Paulo, Brazil.
- 3Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
- 4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- 5Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 6Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
- 7Department of Medicine, Gastroenterology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York.
- 8Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York.
- 9Department of Medicine, Weill Cornell Medical College, New York, New York.
- 10Parker Institute for Cancer Immunotherapy.
- ↵*Corresponding Author:
Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, 300 East 66th Street Floor, New York, NY 10065. Phone: 646-888-4763; Fax: 646-227-7276; E-mail: hellmanm{at}mskcc.org
September 2018
Volume 6, Issue 9
Volume 6, Issue 9
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Jump to section
Advertisement